Literature DB >> 5530558

Studies in mouse L-cells on the incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-beta-D-arabinofuranosylcytosine 5'-triphosphate.

F L Graham, G F Whitmore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5530558

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  46 in total

1.  Mechanistic implications of alterations in HL-60 cell nascent DNA after exposure to 1-beta-D-arabinofuranosylcytosine.

Authors:  D D Ross; D P Cuddy; N Cohen; D R Hensley
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

Authors:  R L Momparler; N Onetto-Pothier; D Y Bouffard; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

4.  In vitro polyoma DNA synthesis: inhibition by 1-beta-d-arabinofuranosyl CTP.

Authors:  T Hunter; B Francke
Journal:  J Virol       Date:  1975-04       Impact factor: 5.103

5.  Modulation of cytosine arabinoside-induced proliferation inhibition by exogenous adenosylmethionine.

Authors:  E Rakasz; J Sugar; O Csuka
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Cytosine-arabinoside does not inhibit incorporation of 3H-thymidine in herpes simplex virus transformed cells.

Authors:  J Roubal
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

7.  Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Authors:  Judith E Karp; Brian M Thomas; Jacqueline M Greer; Christopher Sorge; Steven D Gore; Keith W Pratz; B Douglas Smith; Karen S Flatten; Kevin Peterson; Paula Schneider; Karen Mackey; Tomoko Freshwater; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Douglas E Gladstone; Margaret M Showel; Sabine Loechner; David A Parry; Jo Ann Horowitz; Randi Isaacs; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

8.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Synthesis of DNA and poly(adenosine diphosphate ribose) in normal and chronic lymphocytic leukemia lymphocytes.

Authors:  N A Berger; J W Adams; G W Sikorski; S J Petzold; W T Shearer
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

10.  Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia.

Authors:  A L Harris; C Potter; C Bunch; J Boutagy; D J Harvey; D G Grahame-Smith
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.